Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05340374 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

Study acronym: LuCAB
StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated April 6, 2025 (before its estimated June 20, 2026 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial status: Recruiting to Active, Not Recruiting
    • Enrollment target: estimated 44 to confirmed 35
    • Site details revised at 2 of 2 sites
    v6
  2. Study sites: 1 to 2v5
  3. Re-verified, no change to tracked fieldsv4
  4. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Jun 2022 to Jul 14, 2022
    • Site details revised
    v3
  5. Primary endpoints revised (3)
    • Eligibility criteria expanded, about 10 words
    • Secondary endpoints revised (9)
    • Study description shortened, about 41 words
    v2
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This clinical trial will evaluate the safety of Cabazitaxel in combination with 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer.
Trial Details
NCT Number NCT05340374
Lead Sponsor Peter MacCallum Cancer Centre, Australia
Conditions
(from sponsor)		 Metastatic Castration-resistant Prostate Cancer, mCRPC
Enrollment 35 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov